BindingDB logo
myBDB logout

46 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27692854 100 N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.EBI Boehringer Ingelheim Pharmaceuticals
27096048 80 Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.EBI Peking Union Medical College and Chinese Academy of Medical Sciences
26248802 46 Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.EBI Syntrix Biosystems
25933594 6 Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.EBI Syntrix Biosystems
25708618 30 Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.EBI AstraZeneca
24974342 33 The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.EBI Novartis Institutes for BioMedical Research
25455491 32 2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists.EBI GlaxoSmithKline
25254640 64 Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.EBI Syntrix Biosystems
23516963 99 Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).EBI AstraZeneca
17382543 1 SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction.EBI AstraZeneca
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
18240390 27 Evaluation of a series of bicyclic CXCR2 antagonists.EBI AstraZeneca R&D Charnwood
18308567 44 Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.EBI Johnson& Johnson Pharmaceutical Research and Development
17236763 39 Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.EBI GlaxoSmithKline
17181143 31 Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.EBI Schering-Plough Research Institute
15357956 11 Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.EBI GlaxoSmithKline
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
19713110 27 Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.EBI WuXi PharmaTech Co. Ltd
19525110 46 Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.EBI Schering-Plough Research Institute
19200721 50 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.EBI Schering-Plough Research Institute
19196511 42 Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.EBI Schering-Plough Research Institute
18304809 24 Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.EBI Pharmacopeia, Inc.
18242983 82 Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.EBI Schering-Plough Research Institute
18006311 40 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.EBI Schering-Plough Research Institute
17524641 69 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI GlaxoSmithKline
17459706 42 C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.EBI Schering Plough Research Institute
16934456 36 N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.EBI GlaxoSmithKline
16697193 26 Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.EBI Pharmacopeia Drug Discovery, Inc.
16540318 28 Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.EBI Pharmacopeia Drug Discovery, Inc.
16297626 14 Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.EBI AstraZeneca R&D Charnwood
15771462 125 Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI Pharmaceutical Research Institute
14998320 16 Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.EBI GlaxoSmithKline
12873480 28 Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.EBI AstraZeneca R&D Charnwood
12031332 4 Nicotinanilides as inhibitors of neutrophil chemotaxis.EBI Celltech R&D Inc.
11459668 16 Nicotinamide N-oxides as CXCR2 antagonists.EBI Celltech R&D